Shanghai Dismisses Scientists Following Child's Death in Unapproved Brain Gene-Editing Trial
Two leading researchers were fired and barred from state science programs after an investigation revealed severe safety and ethical lapses in a fatal 2025 CRISPR trial. The team concealed the six-year-old patient's death and accepted over $1 million in funding and gifts from her family.
Share this story
Shanghai authorities have dismissed two leading scientists and penalized several hospital officials following an investigation into the death of a six-year-old girl during an experimental brain gene-editing trial. The disciplinary actions mark the conclusion of a high-profile probe into severe clinical misconduct.[1][2]
The municipal investigation team released its findings on November 13, detailing extensive ethical and safety lapses at Shanghai Jiao Tong University School of Medicine and its affiliated Xinhua Hospital. The report outlined a pattern of regulatory evasion throughout the trial's lifecycle.[3][5]
The child, who suffered from a rare neurodevelopmental disorder, died in March 2025, just days after receiving a custom CRISPR-derived base editor injection into her spinal fluid. The procedure was the world's first known attempt to edit genes inside a living human brain.[2][4]
The Investigation Findings
Investigators concluded that the research team, led by Qiu Zilong and Yang Kan, bypassed critical safety protocols prior to the human trial. Crucially, they failed to share concerning non-human primate toxicology data with the clinical lead overseeing the patient's care.[2][6]
The ethics committee at Xinhua Hospital approved the study in January 2025 despite this glaring lack of sufficient safety evidence. Furthermore, the consent forms provided to the family did not prominently state the risk of death associated with the experimental procedure.[2]
Authorities also uncovered significant financial irregularities surrounding the unauthorized trial. The investigation noted that the patient's family contributed 5.337 million yuan, or approximately $800,000, directly toward the research project in hopes of securing a cure.[1][2]
In addition to the project funding, the researchers accepted roughly 1.06 million yuan in personal cash and gifts from the family. These illicit payments, which included expensive liquor and electronics, have since been returned or surrendered to authorities.[2]
The Experimental Treatment
The patient had Snijders Blok-Campeau syndrome, a rare genetic condition caused by mutations in the CHD3 gene. The disorder is characterized by severe intellectual disability and speech impairment, and it currently has no approved treatments available anywhere in the world.[2][3]
Driven by desperation, the family approached Qiu in July 2023, hoping his laboratory could design a customized therapy. Their goal was to correct the single faulty letter in the girl's DNA code that was responsible for her debilitating condition.[1][2]
The research team utilized a base editor, a highly precise CRISPR-derived tool designed to chemically convert one DNA letter into another. Unlike traditional CRISPR systems, base editors achieve this without creating potentially dangerous double-strand breaks in the genome.[2]
To deliver the editing machinery into the brain cells, the scientists packaged the genetic instructions inside two adeno-associated virus vectors. While common in gene therapy, this delivery method is immunologically complex and carries significant risks at high doses.[1][2]
The child received the experimental injection directly into her spinal fluid on March 24, 2025. Her condition rapidly deteriorated following the procedure, and despite intensive medical intervention, she died seven days later on March 31.[2]
An emergency ethics review convened on April 2 attributed her death to thrombotic microangiopathy. This severe immune and clotting complication is increasingly recognized as a fatal risk associated with high-dose viral vector therapies.[2]
Publication and Cover-Up
Despite the fatal outcome of the human trial, Qiu's team proceeded to publish their preclinical results in the prestigious journal Nature nearly a year later, in February 2026. The published paper highlighted the technique's potential for human application.[2]
The Nature publication omitted any mention of the child's death, or the fact that a human trial had even taken place. The researchers also failed to disclose the liver and kidney damage observed during their earlier non-human primate safety tests.[2][3]
While the Shanghai municipal investigation found no outright data fabrication in the Nature paper, it identified significant academic irregularities. These included discrepancies in the reported methods and the unexplained repeated presentation of data from a single batch.[1][3]
The fatal trial remained entirely hidden from the broader scientific community for more than a year. It was finally exposed in July 2026, when a joint investigation by Science and Retraction Watch brought the tragedy to public attention and prompted the official probe.[1][2]
Penalties and Institutional Fallout
As a direct result of the probe, Qiu and Yang were formally dismissed from their academic and clinical positions. The disciplinary action severs their ties with Shanghai Jiao Tong University School of Medicine and its affiliated research institutes.[3][6]
Both scientists were barred for five years from participating in state-funded science programs, applying for grants, or competing for national research awards. They have also been entered into a national database tracking serious research integrity violations.[1][2]
The clinical study's lead investigator at Xinhua Hospital, surnamed Yu, was removed as head of the research department and demoted. Investigators determined he failed to adequately review the preclinical safety data before proceeding with the human injection.[2][3]
The head of the hospital's ethics committee office, surnamed Shi, was also demoted for his role in the oversight failure. The committee had approved the high-risk study without demanding sufficient toxicology evidence from the research team.[2]
"The investigation found that Qiu's team from the Songjiang Research Institute and relevant personnel from Xinhua Hospital did not strictly adhere to relevant regulations during the research," the municipal task force stated in its official release.[3]
Consequently, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, and Songjiang District Central Hospital were summoned for talks. The institutions were issued administrative penalties and ordered to implement comprehensive supervisory reforms to prevent future ethical breaches.[1][3]
Regulatory Implications
The incident highlights critical vulnerabilities in China's dual-track regulatory system, which governs how experimental medical treatments transition from the laboratory to human patients. The framework relies heavily on local oversight rather than centralized national approval.[2]
Under this system, doctors at major hospitals can test novel therapies through investigator-initiated trials after securing local ethical review. They do not require prior clearance from the national drug administration to administer experimental treatments to desperate patients.[2]
While this decentralized approach has accelerated domestic biotech development and expanded access to experimental care, it places immense responsibility on hospital ethics committees. These local boards are often ill-equipped to evaluate the complex safety profiles of emerging genetic technologies.[2][7]
In response to the tragedy, the Shanghai Municipal Health Commission announced a special inspection campaign. The initiative will target all clinical research within the municipality that utilizes emerging biomedical technologies, aiming to close existing regulatory loopholes.[2]
Key points
- Shanghai authorities dismissed researchers Qiu Zilong and Yang Kan following the death of a six-year-old girl in an experimental brain gene-editing trial.
- The investigators found the team bypassed safety protocols, ignored primate toxicology warnings, and accepted over $1 million in funding and gifts from the family.
- The researchers published their preclinical results in Nature nearly a year later without disclosing the child's death or the adverse animal data.
- The incident has prompted the Shanghai Municipal Health Commission to launch a targeted inspection campaign of clinical research involving emerging biomedical technologies.
What we don’t know
- It remains unclear whether the researchers will face criminal charges beyond their academic dismissals and administrative penalties.
- The exact nature of the administrative penalties levied against the involved hospitals has not been fully detailed by the municipal task force.
- It is unknown how the journal Nature will address the identified academic irregularities and omissions in the researchers' February 2026 publication.
How we got here
July 2023
The patient's family approaches researcher Qiu Zilong to design a custom gene-editing treatment.
January 2025
Xinhua Hospital's ethics committee approves the experimental study despite insufficient safety evidence.
March 2025
The child receives the viral vector injection and dies seven days later from thrombotic microangiopathy.
February 2026
The research team publishes preclinical results in Nature, omitting the human trial and the child's death.
July 2026
A joint investigation by Science and Retraction Watch exposes the fatal trial to the public.
November 2026
Shanghai authorities release their findings, dismissing the researchers and penalizing hospital officials.
- Municipal Investigators
- Shanghai authorities emphasize the need for strict adherence to clinical regulations and ethical oversight.
- Bioethics Community
- Global bioethicists warn of the dangers inherent in investigator-initiated trials for emerging genetic therapies.
Perspectives this story doesn't cover
- The patient's family
- Nature journal editorial board
Sources
[1]South China Morning PostBioethics CommunityChinese scientists fired after child dies in world's first brain gene-editing attempt
Read on South China Morning Post →
[2]Sixth ToneMunicipal InvestigatorsShanghai Sacks Two Scientists Over Child's Death in Gene Trial
Read on Sixth Tone →
[3]China DailyMunicipal InvestigatorsShanghai releases investigation results on gene-editing research incident
Read on China Daily →
[4]Fierce BiotechBioethics CommunityChinese scientists fired after child dies in gene editing study: report
Read on Fierce Biotech →
[5]City News ServiceMunicipal InvestigatorsShanghai Dismisses Researchers After Probe Into Child's Death in Gene Therapy Study
Read on City News Service →
[6]Caixin GlobalBioethics CommunityShanghai Fires Gene-Editing Researcher After Child's Death
Read on Caixin Global →
[7]Hindustan TimesBioethics CommunityChina finds ethical flaw in gene-editing trial that led to child's death; two researchers fired
Read on Hindustan Times →
More in Science
See all →CRISPR Technology
New Sequencing Tool Tracks Off-Target CRISPR Gene Edits Across Individual Cells
6 sources
Evolutionary Genetics
Inherited Neanderthal Gene Variant Linked to Lower Schizophrenia Risk in Modern Humans
5 sources
Genetic Networks
X-Linked ZFX Gene Regulates Genetic Networks Shielding Females From Autism
5 sources
Viral Pathogenesis
Single Amino Acid Mutation Governs Andes Virus Pathogenicity in Human Cells
5 sources
Comments
Every angle. Every day.
Get Science stories with full source coverage and perspective breakdowns, free every day.




